Biotech Startup Exsure Raises Rs 3 Cr Funding In Seed Round

Exsure, a biotech startup has raised Rs 3 Crore funding in a seed round led by Unicorn India Ventures. 

Funding Utilisation

The startup plans to use the funds to finish the non-clinical study of its exosome-based drug delivery system. The proceeds will also support Exsure’s global expansion, help promote its in-house R&D products, and boost brands like Exosure, Leucosure, PlantExosure and Dr Berries.

Read also- Jio Financial Services and BlackRock Invest Rs 117 Cr In Mutual Fund Business

“During our PhD journey, we witnessed the toxicity of the present-day chemotherapy drugs and how 13% of the in-treatment cancer patients die due to toxicity of the chemotherapy drugs. Exsure is on a mission to reduce the toxicity of the chemotherapy drugs and make them more targeted to the cancerous cells. Our vision is to empower millions of cancer patients around the world and improve their quality of life," said Swastika Paul, CSO & Co-founder at Exsure.

Bhaskar Majumdar, Managing Partner, Unicorn India Ventures, said, "The fear of Big C is real not just for the patients but even their families. Exsure with its advancement in scientific tools, technology and cutting edge medical research has built a powerful Exosome based drug that commits to staying at the forefront of advancement in therapeutics science. The funding accelerates Exsure’s mission to deploy solutions at a global level. We believe Exsure will not only continue to sustain its momentum but also grow due to its potential for transformative breakthroughs through its nano delivery platform. The company has witnessed remarkable progress in the last 12 months and has launched more innovative products. Hence, we believe the market opportunity is huge and the company has built the right momentum to capitalise on this segment.” 

In the past 12 months, Exsure has started a non-clinical study in India in partnership with a CRO and reached a milestone in its preclinical study using its patented technology. The company also reported five times growth in the last fiscal year and plans to serve over 50 clients this year with its R&D products: Exosure (a 3-in-1 exosome isolation reagent), Leucosure (PBMC isolation reagent) and PlantExosure (India’s first plant exosome isolation reagent). It has also been selected for the OIST Innovation Accelerator program in Japan to expand its business and conduct clinical trials.

About Exsure 

Bhubaneswar-based Exsure was founded in 2021 by Swastika Paul and Abhishek Dutta; it is a biotech startup focused on reducing the side effects and toxicity of anti-cancer drugs using its patented exosomal drug-delivery platform, which targets both cancer and cancer stem cells.

The company’s advanced technology aims to lessen chemotherapy's toxic effects and reduce the chances of cancer returning, improving the quality of life for cancer patients.

Startup Funding News: Your Gateway to Every Funding Update.

Advertisment

Latest Startup News: Stay updated with the latest startup news and trends. Your go-to source for startup ecosystem updates.

Startup Stories: Discover inspiring tales of startups overcoming challenges and achieving success.